Global Integrin Beta 1 Market

Integrin Beta 1 Comprehensive Study by Type (AXT-108, C-16Y, CLT-28643, SAL-021, Others), Application (Genetic Disorders, Dermatology, Cardiovascular, Others) Players and Region - Global Market Outlook to 2030

Integrin Beta 1 Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Integrin Beta 1
Integrin beta-1 (ITGB1) is a cell surface receptor that in the human body is encoded by the ITGB1 gene. This integrin associates with integrin alpha 2 and integrin alpha 1 to form integrin complexes that function as collagen receptors. Members of the integrin family are membrane receptors involved in cell recognition and adhesion in different processes including hemostasis, embryogenesis, immune response, and tissue repair. Increasing applications of ITGB1 in treatments of genetic disorders, dermatology, cardiovascular disorders fueling market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is seeing less number of market players, the key leading vendors are highly focused on the production technologies, efficiency enhancement, and product life. There is various growth opportunity in this market which is captured by leading players via tracking the ongoing process enhancement and huge investment in market growth strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Integrin Beta 1 market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Avipero Ltd (United Kingdom), Clanotech AB (Sweden), Morphic Therapeutic Inc. (United States) and Strykagen Corp (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Integrin Beta 1 market by Type (AXT-108, C-16Y, CLT-28643, SAL-021 and Others), Application (Genetic Disorders, Dermatology, Cardiovascular and Others) and Region.



On the basis of geography, the market of Integrin Beta 1 has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Influencing Trend:
Increasing Application in Treatment of Cardiovascular Disorders

Market Growth Drivers:
Increasing Application in Treatment of Genetic Disorders and Growing Healthcare Infrastructure in the Developing Economies

Challenges:
Lack of Awareness in the Emerging Economies

Restraints:
Stringent Government Regulations

Opportunities:
Growing Application in Treatment of Dermatological Disorders and Increasing Spending Of R&D Activities in Healthcare Sector




Key Target Audience
Government Agencies, Commercial Research & Development Institutions, Government Organizations, Research Organizations, and Consulting Firms, Trade Associations and Industry Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • AXT-108
  • C-16Y
  • CLT-28643
  • SAL-021
  • Others
By Application
  • Genetic Disorders
  • Dermatology
  • Cardiovascular
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Application in Treatment of Genetic Disorders
      • 3.2.2. Growing Healthcare Infrastructure in the Developing Economies
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. Increasing Application in Treatment of Cardiovascular Disorders
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Integrin Beta 1, by Type, Application and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Integrin Beta 1 (Value)
      • 5.2.1. Global Integrin Beta 1 by: Type (Value)
        • 5.2.1.1. AXT-108
        • 5.2.1.2. C-16Y
        • 5.2.1.3. CLT-28643
        • 5.2.1.4. SAL-021
        • 5.2.1.5. Others
      • 5.2.2. Global Integrin Beta 1 by: Application (Value)
        • 5.2.2.1. Genetic Disorders
        • 5.2.2.2. Dermatology
        • 5.2.2.3. Cardiovascular
        • 5.2.2.4. Others
      • 5.2.3. Global Integrin Beta 1 Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Integrin Beta 1 (Price)
      • 5.3.1. Global Integrin Beta 1 by: Type (Price)
  • 6. Integrin Beta 1: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Avipero Ltd (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Clanotech AB (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Morphic Therapeutic Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Strykagen Corp (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Integrin Beta 1 Sale, by Type, Application and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Integrin Beta 1 (Value)
      • 7.2.1. Global Integrin Beta 1 by: Type (Value)
        • 7.2.1.1. AXT-108
        • 7.2.1.2. C-16Y
        • 7.2.1.3. CLT-28643
        • 7.2.1.4. SAL-021
        • 7.2.1.5. Others
      • 7.2.2. Global Integrin Beta 1 by: Application (Value)
        • 7.2.2.1. Genetic Disorders
        • 7.2.2.2. Dermatology
        • 7.2.2.3. Cardiovascular
        • 7.2.2.4. Others
      • 7.2.3. Global Integrin Beta 1 Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Integrin Beta 1 (Price)
      • 7.3.1. Global Integrin Beta 1 by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Integrin Beta 1: by Type(USD Million)
  • Table 2. Integrin Beta 1 AXT-108 , by Region USD Million (2018-2023)
  • Table 3. Integrin Beta 1 C-16Y , by Region USD Million (2018-2023)
  • Table 4. Integrin Beta 1 CLT-28643 , by Region USD Million (2018-2023)
  • Table 5. Integrin Beta 1 SAL-021 , by Region USD Million (2018-2023)
  • Table 6. Integrin Beta 1 Others , by Region USD Million (2018-2023)
  • Table 7. Integrin Beta 1: by Application(USD Million)
  • Table 8. Integrin Beta 1 Genetic Disorders , by Region USD Million (2018-2023)
  • Table 9. Integrin Beta 1 Dermatology , by Region USD Million (2018-2023)
  • Table 10. Integrin Beta 1 Cardiovascular , by Region USD Million (2018-2023)
  • Table 11. Integrin Beta 1 Others , by Region USD Million (2018-2023)
  • Table 12. South America Integrin Beta 1, by Country USD Million (2018-2023)
  • Table 13. South America Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 14. South America Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 15. Brazil Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 16. Brazil Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 17. Argentina Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 18. Argentina Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 19. Rest of South America Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 20. Rest of South America Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 21. Asia Pacific Integrin Beta 1, by Country USD Million (2018-2023)
  • Table 22. Asia Pacific Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 23. Asia Pacific Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 24. China Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 25. China Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 26. Japan Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 27. Japan Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 28. India Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 29. India Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 30. South Korea Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 31. South Korea Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 32. Taiwan Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 33. Taiwan Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 34. Australia Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 35. Australia Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 38. Europe Integrin Beta 1, by Country USD Million (2018-2023)
  • Table 39. Europe Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 40. Europe Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 41. Germany Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 42. Germany Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 43. France Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 44. France Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 45. Italy Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 46. Italy Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 47. United Kingdom Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 48. United Kingdom Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 49. Netherlands Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 50. Netherlands Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 51. Rest of Europe Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 52. Rest of Europe Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 53. MEA Integrin Beta 1, by Country USD Million (2018-2023)
  • Table 54. MEA Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 55. MEA Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 56. Middle East Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 57. Middle East Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 58. Africa Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 59. Africa Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 60. North America Integrin Beta 1, by Country USD Million (2018-2023)
  • Table 61. North America Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 62. North America Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 63. United States Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 64. United States Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 65. Canada Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 66. Canada Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 67. Mexico Integrin Beta 1, by Type USD Million (2018-2023)
  • Table 68. Mexico Integrin Beta 1, by Application USD Million (2018-2023)
  • Table 69. Integrin Beta 1: by Type(USD/Units)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Integrin Beta 1: by Type(USD Million)
  • Table 75. Integrin Beta 1 AXT-108 , by Region USD Million (2025-2030)
  • Table 76. Integrin Beta 1 C-16Y , by Region USD Million (2025-2030)
  • Table 77. Integrin Beta 1 CLT-28643 , by Region USD Million (2025-2030)
  • Table 78. Integrin Beta 1 SAL-021 , by Region USD Million (2025-2030)
  • Table 79. Integrin Beta 1 Others , by Region USD Million (2025-2030)
  • Table 80. Integrin Beta 1: by Application(USD Million)
  • Table 81. Integrin Beta 1 Genetic Disorders , by Region USD Million (2025-2030)
  • Table 82. Integrin Beta 1 Dermatology , by Region USD Million (2025-2030)
  • Table 83. Integrin Beta 1 Cardiovascular , by Region USD Million (2025-2030)
  • Table 84. Integrin Beta 1 Others , by Region USD Million (2025-2030)
  • Table 85. South America Integrin Beta 1, by Country USD Million (2025-2030)
  • Table 86. South America Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 87. South America Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 88. Brazil Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 89. Brazil Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 90. Argentina Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 91. Argentina Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 92. Rest of South America Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 93. Rest of South America Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 94. Asia Pacific Integrin Beta 1, by Country USD Million (2025-2030)
  • Table 95. Asia Pacific Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 96. Asia Pacific Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 97. China Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 98. China Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 99. Japan Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 100. Japan Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 101. India Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 102. India Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 103. South Korea Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 104. South Korea Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 105. Taiwan Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 106. Taiwan Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 107. Australia Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 108. Australia Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 109. Rest of Asia-Pacific Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 110. Rest of Asia-Pacific Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 111. Europe Integrin Beta 1, by Country USD Million (2025-2030)
  • Table 112. Europe Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 113. Europe Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 114. Germany Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 115. Germany Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 116. France Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 117. France Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 118. Italy Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 119. Italy Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 120. United Kingdom Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 121. United Kingdom Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 122. Netherlands Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 123. Netherlands Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 124. Rest of Europe Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 125. Rest of Europe Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 126. MEA Integrin Beta 1, by Country USD Million (2025-2030)
  • Table 127. MEA Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 128. MEA Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 129. Middle East Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 130. Middle East Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 131. Africa Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 132. Africa Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 133. North America Integrin Beta 1, by Country USD Million (2025-2030)
  • Table 134. North America Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 135. North America Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 136. United States Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 137. United States Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 138. Canada Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 139. Canada Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 140. Mexico Integrin Beta 1, by Type USD Million (2025-2030)
  • Table 141. Mexico Integrin Beta 1, by Application USD Million (2025-2030)
  • Table 142. Integrin Beta 1: by Type(USD/Units)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Integrin Beta 1: by Type USD Million (2018-2023)
  • Figure 5. Global Integrin Beta 1: by Application USD Million (2018-2023)
  • Figure 6. South America Integrin Beta 1 Share (%), by Country
  • Figure 7. Asia Pacific Integrin Beta 1 Share (%), by Country
  • Figure 8. Europe Integrin Beta 1 Share (%), by Country
  • Figure 9. MEA Integrin Beta 1 Share (%), by Country
  • Figure 10. North America Integrin Beta 1 Share (%), by Country
  • Figure 11. Global Integrin Beta 1: by Type USD/Units (2018-2023)
  • Figure 12. Global Integrin Beta 1 share by Players 2023 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Avipero Ltd (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 15. Avipero Ltd (United Kingdom) Revenue: by Geography 2023
  • Figure 16. Clanotech AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 17. Clanotech AB (Sweden) Revenue: by Geography 2023
  • Figure 18. Morphic Therapeutic Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Morphic Therapeutic Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Strykagen Corp (United States) Revenue, Net Income and Gross profit
  • Figure 21. Strykagen Corp (United States) Revenue: by Geography 2023
  • Figure 22. Global Integrin Beta 1: by Type USD Million (2025-2030)
  • Figure 23. Global Integrin Beta 1: by Application USD Million (2025-2030)
  • Figure 24. South America Integrin Beta 1 Share (%), by Country
  • Figure 25. Asia Pacific Integrin Beta 1 Share (%), by Country
  • Figure 26. Europe Integrin Beta 1 Share (%), by Country
  • Figure 27. MEA Integrin Beta 1 Share (%), by Country
  • Figure 28. North America Integrin Beta 1 Share (%), by Country
  • Figure 29. Global Integrin Beta 1: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Avipero Ltd (United Kingdom)
  • Clanotech AB (Sweden)
  • Morphic Therapeutic Inc. (United States)
  • Strykagen Corp (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 178 Pages 65 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Integrin Beta 1 Market Quantitative research analysis
Global Integrin Beta 1 Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Avipero Ltd (United Kingdom), Clanotech AB (Sweden), Morphic Therapeutic Inc. (United States) and Strykagen Corp (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Application in Treatment of Cardiovascular Disorders" is seen as one of major influencing trends for Integrin Beta 1 Market during projected period 2023-2030.
The Integrin Beta 1 market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Integrin Beta 1 Market Report?

Have a Query? Click Here

Other Related Reports

Digestive Enzyme Supplements Comprehensive Study by Type (Bromelain, Lipase, Papain, Lactase), Application (Infant Nutrition, Medical Nutrition, Sports Nutrition, Other), Origin (Animal, Plant, Micro...
$ 3650
Optogenetics Comprehensive Study by Application (Retinal disease treatment, Neuroscience, Cardioversion, Pacing, Others), Actuators (Halorhodospin, Channelrhodospin, Archaerhodospin), Sensor Type (Ge...
$ 3800
Pharmacogenomics Comprehensive Study by Technology (Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Others), End User (Hospitals & Clinics, Research Institu...
$ 3750
Magnetic Beads Comprehensive Study by Application (Human Cell Separation, Animal cell separation (clinical study), Secondary cell separation), End Users (Healthcare Facilities (Hospitals, Clinics, an...
$ 3750
Bioanalytical Services Comprehensive Study by Type (Discovery bioanalysis services, Non-clinical bioanalysis services, Clinical bioanalysis services), Application (Pharmaceutical Industry, Biotechnol...
$ 3750
Rapid Influenza Diagnostic Test Comprehensive Study by Type (Digital RIDTs, Conventional RIDT), Application (Hospitals & Clinics, Laboratories, Other), Test (Point-of-Care test, Nucleic Acid Test, Im...
$ 3350